Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer
DA Yardley, HA Burris III, T Markus, DR Spigel… - Clinical breast …, 2009 - Elsevier
Background Inhibition of the platelet-derived growth factor receptor (PDGFR) might improve
the efficacy of chemotherapy by lowering interstitial tumor pressure and allowing increased
tumor penetration by cytotoxic agents. In this phase II trial, we added imatinib, a PDGFR
inhibitor, to docetaxel in the first-line treatment of women with metastatic breast cancer
(MBC). Patients and Methods Women with MBC who had received a maximum of 1 previous
chemotherapy regimen were eligible for this trial. Initially, patients received oral imatinib 600 …
the efficacy of chemotherapy by lowering interstitial tumor pressure and allowing increased
tumor penetration by cytotoxic agents. In this phase II trial, we added imatinib, a PDGFR
inhibitor, to docetaxel in the first-line treatment of women with metastatic breast cancer
(MBC). Patients and Methods Women with MBC who had received a maximum of 1 previous
chemotherapy regimen were eligible for this trial. Initially, patients received oral imatinib 600 …